[ @entity4140 and XXXX in the treatment of duodenal @entity1066 ].

@entity4444 @entity1 @entity2133 @entity1066 @entity4140 @entity1142
The efficacy of @entity4140 --of anticholinergic effect--and the H2-receptor blocking @entity4444 has been studied in duodenal @entity1066 with random, double blind fashion. Recurrence examinations were carried out 6 and 12 months following the treatment. 50 @entity1 were given @entity4140 and 50 @entity4444 . The average age of the @entity1 was 44.5 and 43.8 years respectively. Of them 60 (24 + 36) were @entity1 and 40 (26 + 14) @entity1 . At the start, 6 weeks following the start 6 and 12 months after the finishing of the treatment gastroscopy was performed. In the course of the six-week-long treatment 38 (76%) of the @entity4140 taking @entity1 and 36 (72%) of the @entity4444 taking @entity1 recovered. No significant difference was found between the efficacy of the both treatments. In the respect of the half and one year recurrence, no significant difference was observed between the two @entity1 groups. Ten of the @entity1 taking @entity4140 and 4 of those taking @entity4444 complained of side effects. @entity2133 , visual disturbance in the former group and @entity1142 in the latter one. On the basis of the examinations both secretion inhibitors were found equally suitable for the therapy of duodenal @entity1066 .
